MammaPrint and OVHIPEC are awarded Patient Impact Award

10-12-2018

On Monday, December 10th, the MammaPrint team and the OVHIPEC team were awarded the first two NKI Patient Impact Awards. Medical Director Emile Voest awarded the prizes to Willemien van Driel, who represented the OVHIPEC team, and to René Bernards and Emiel Rutgers from the MammaPrint team.

HIPEC for ovarium carcinoma (OV-HIPEC)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a combination of surgery and chemotherapy that is being used in patients with peritoneal metastases from colorectal cancer. After surgical removal of visible tumors and metastases, heated chemotherapy is circulated in the abdomen to treat possible residual disease. Many patients with ovarian carcinoma face peritoneal metastases as well. That’s why gynecologist Willemien van Driel and colleagues performed a large clinical trial with HIPEC in these patients (OVHIPEC). This study recently showed that the treatment increases the 5-year overall survival by 10 percent.

MammaPrint
MammaPrint, also known as the 70-gene signature, was developed between 2000 and 2002 in the Rene Bernards lab as a tool to help identify patients with early-stage breast cancer that can safely forego chemotherapy. Once the 70-gene signature had been discovered and validated in a first independent validation cohort, clinicians like Sabine Linn and surgeon Emiel Rutgers were crucial for the validation studies RASTER and MINDACT that helped in clinical acceptance of the gene signature.

Symposium & artist impression
Both teams will receive 10.000 euros to organize a symposium for a patient-related audience as well as an artist's impression of their innovation.

Shortlist
From the competing teams the NKI Board selected three teams; this shortlist was judged by an international jury. The third on this list was the MARI-procedure team. Surgeon Marie-Jeanne Vrancken Peeters and colleagues developed a procedure that can prevent unnecessary axillary lymph node dissections.

The Patient Impact Award
In 2018, the Patient Impact Award was installed by the Board of the NKI in order to highlight the many practice-changing clinical innovations developed within the NKI that benefit cancer patients.

MammaPrint and OVHIPEC are awarded Patient Impact Award

This site uses cookies